# A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis

> **NCT00562783** · PHASE2 · COMPLETED · sponsor: **Hospital Authority, Hong Kong** · enrollment: 90 (estimated)

## Conditions studied

- Hepatitis B
- Hepatitis C
- Liver Cirrhosis

## Interventions

- **DRUG:** Vitaliver
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00562783
- **Lead sponsor:** Hospital Authority, Hong Kong
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** —
- **Final completion:** 2006-05
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2013-10-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562783, "A Phase II, Double-blinded, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Vitalliver in Patients With Decompensated Cirrhosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00562783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*